Randomised trial to identify the safest and most effective selenium compound for cancer patients

Phase 1

Recruiting

• Conditions: Cancer; Cancer - Leukaemia - Chronic leukaemia; Cancer - Any cancer

• Registration Number: ACTRN12613000118707
• Lead Sponsor: Waikato District Health Board

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-31
• Last Update Posted: 14 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Subjects with either chronic lymphocytic leukaemia (peripheral blood lymphocyte count > 10 x 10^9/l) or metastatic cancer, in whom the use of chemotherapy is not anticipated in the next 3 months
2. Adequate liver, renal and bone marrow function
3. ECOG performance status 0-2
4. Life expectancy over 6 months

Exclusion Criteria

1. Subjects treated within the last 4 weeks with cytotoxic chemotherapy, anticancer biological therapy (excluding hormonal therapy for prostate cancer) or radiotherapy
2. Unable to swallow or absorb study tablets
3. Concurrent selenium supplements over 100 mcg/day

Study & Design

• Study Type: Interventional
• Study Design: Not specified